Podowart: Effective Topical Treatment for Warts
Podowart
| Product dosage: 10 ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 3 | 25.74 $ | 77.22 $ (0%) | 🛒 Add to cart |
| 6 | 23.40 $ | 154.44 $ 140.40 $ (9%) | 🛒 Add to cart |
| 9 | 22.75 $ | 231.66 $ 204.75 $ (12%) | 🛒 Add to cart |
| 10 | 22.23 $
Best per bottle | 257.40 $ 222.30 $ (14%) | 🛒 Add to cart |
Synonyms | |||
Podowart is a clinically formulated topical solution designed for the targeted removal of common warts and verrucae. Its active ingredient, podophyllotoxin, works by inhibiting cell division, leading to the gradual destruction of wart tissue. This prescription treatment offers a precise, physician-recommended approach for patients seeking an effective, at-home solution for benign epidermal growths. Proper application ensures minimal discomfort and promotes healthy skin regeneration.
Features
- Contains 0.5% podophyllotoxin as the active pharmaceutical ingredient
- Available in solution or gel form for easy, controlled application
- Designed for external use only on keratinized skin
- Supplied with applicators for precise targeting of affected areas
- Stable formulation with a shelf life of 24 months when stored correctly
Benefits
- Effectively eliminates common warts and verrucae through targeted cytostatic action
- Reduces recurrence rates when used as directed under medical supervision
- Minimizes damage to surrounding healthy tissue through precise application
- Convenient at-home treatment regimen reduces need for clinical procedures
- Promotes restoration of normal skin appearance post-treatment
- Cost-effective alternative to cryotherapy or surgical removal
Common use
Podowart is primarily indicated for the treatment of external genital warts (condylomata acuminata) and common non-genital warts caused by human papillomavirus (HPV). It is particularly effective on softer, non-keratinized warts but can be used on various wart types under medical guidance. Physicians may recommend it for patients who have not responded to other treatments or who prefer a self-applied topical solution. The product is not intended for mucosal surfaces or perianal warts without specific medical direction.
Dosage and direction
Apply Podowart twice daily (morning and evening) for 3 consecutive days, followed by a 4-day treatment-free interval. This one-week cycle may be repeated for up to 4 weeks or as directed by a physician. Using the supplied applicator, apply sufficient solution to cover the wart completely without spreading to surrounding skin. Allow the treated area to dry completely before contact with clothing or skin surfaces. Wash hands thoroughly after application. Do not exceed recommended frequency or duration of use.
Precautions
Use only as directed by a healthcare professional. Avoid contact with eyes, mucous membranes, and broken skin. Do not apply to large areas or multiple warts simultaneously without medical supervision. Pregnant women should not handle or use Podowart due to potential systemic absorption and teratogenic risk. Use effective contraception during treatment. Discontinue use and consult a physician if excessive irritation, pain, or inflammation occurs. Keep out of reach of children and pets.
Contraindications
Podowart is contraindicated in patients with known hypersensitivity to podophyllotoxin or any component of the formulation. Do not use on bleeding warts, diabetic patients with peripheral circulatory disorders, or immunocompromised individuals without specialist supervision. Contraindicated during pregnancy and breastfeeding. Not recommended for children under 12 years unless specifically prescribed by a physician experienced in pediatric dermatology.
Possible side effect
Common side effects include localized erythema, burning sensation, itching, and pain at application site. These typically resolve within 2-3 days of treatment cessation. Less frequently, patients may experience erosion, ulceration, or dermatitis. Systemic absorption may rarely cause nausea, vomiting, or peripheral neuropathy. If severe reactions occur or symptoms persist, discontinue use and seek medical attention. Allergic contact dermatitis has been reported in some cases.
Drug interaction
No specific drug interactions have been clinically established with topical podophyllotoxin. However, concomitant use with other topical treatments (especially those containing salicylic acid or retinoids) may increase skin irritation. Consult your physician before using Podowart if you are applying any other medications to the affected area. Systemic interactions are unlikely due to minimal absorption through intact skin.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Continue with the regular dosing schedule. Maintaining the 3-days-on, 4-days-off cycle is crucial for treatment efficacy and skin recovery.
Overdose
Excessive application may lead to increased local reactions including severe pain, inflammation, and tissue necrosis. Systemic toxicity symptoms (nausea, vomiting, neurological symptoms) are rare but possible with very large applications. In case of suspected overdose, remove any remaining product by washing with soap and water. Seek immediate medical attention if systemic symptoms occur. Provide supportive care as symptoms indicate.
Storage
Store at room temperature (15-30°C) in the original container. Keep tightly closed and protected from light. Do not freeze. Keep away from heat and open flame. Discard any unused product 28 days after first opening. Do not transfer to other containers. Proper disposal should follow local regulations for pharmaceutical waste.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Use only as prescribed by a physician. The manufacturer is not liable for misuse or incorrect application. Individual results may vary based on wart type, patient compliance, and physiological factors.
Reviews
Clinical studies demonstrate 45-80% complete clearance rates after 4 weeks of treatment, with patient satisfaction scores averaging 4.2/5. Dermatologists report good efficacy for small-to-medium sized warts with proper patient selection. Most users report noticeable improvement within 2 weeks of initiated therapy. Some patients note temporary discomfort during application, but majority consider benefits outweigh temporary side effects. Long-term follow-up shows recurrence rates of approximately 15-30% at 6 months post-treatment.